deshola Malawi moves to contain a fresh cholera threat, its latest vaccine rollout offers a sharp reminder that some of Africa’s deadliest diseases persist not because solutions are unknown, but because the systems required to sustain them remain fragile.
Health authorities this week began administering oral cholera vaccines in high-risk neighbourhoods of Blantyre after a spike in cases linked to flooding and contaminated water sources. The initial delivery of about 24,000 doses is modest, targeted at the most exposed communities, and shaped by global shortages that have constrained access to vaccines across the developing world. It is a familiar pattern: urgency colliding with limited supply.
Cholera, an acute diarrhoeal disease spread through unsafe water and poor sanitation, has surged across Africa in recent years. According to Africa CDC, the continent recorded more than 300,000 cases last year, the highest toll in a quarter of a century. Climate-driven flooding, rapid urbanisation and long-standing infrastructure deficits have combined to keep the disease entrenched, particularly in informal settlements and rural areas.
Malawi’s vulnerability is well known. Its devastating 2022–23 outbreak killed hundreds and infected tens of thousands before authorities declared it over last year. Yet the conditions that fuelled that crisis unreliable water supply, overstretched health facilities and weak sanitation systems were never fully resolved. Seasonal rains have once again exposed those gaps.
Vaccination, in this context, is a necessary but incomplete answer. Oral cholera vaccines are effective in reducing transmission during outbreaks and buying time for health systems to respond. In Blantyre’s Chilomoni township, where residents often rely on unsafe water when piped supply fails, even limited coverage can blunt the immediate risk. But vaccines do not fix contaminated wells, broken sewage lines or overcrowded housing.
That reality places Malawi’s campaign within a broader continental dilemma. African governments have become more adept at emergency response mobilising vaccines, deploying rapid response teams and coordinating with partners, yet far less successful at translating crisis measures into durable public health infrastructure.
The global shortage of cholera vaccines has only sharpened that tension. Demand has surged as outbreaks flare simultaneously across multiple regions, forcing countries like Malawi to ration doses and prioritise hotspots. This has revived interest in expanding vaccine production closer to home, including clinical trials and manufacturing initiatives in southern Africa. Local production would not eliminate cholera, but it would reduce dependence on strained global stockpiles and slow international supply chains.
In the short term, Malawi’s goal is containment: preventing deaths, limiting spread during the rainy season and stabilising communities already under economic and environmental strain. In the longer term, the challenge is structural. Ending cholera requires sustained investment in clean water, sanitation and hygiene the unglamorous but decisive foundations of public health.
There are signs of movement. National plans increasingly link cholera control to broader development targets, aligning health policy with water infrastructure, urban planning and climate adaptation. Community-based surveillance and early warning systems are being strengthened, recognising that outbreaks are often detected too late. But progress is uneven, and funding remains vulnerable to shifting donor priorities.
Malawi’s experience carries lessons beyond its borders. Cholera thrives where governance falters, infrastructure decays and inequality concentrates risk. Vaccines can suppress outbreaks, but they cannot substitute for functioning systems. As climate shocks intensify and urban populations grow, the cost of inaction will only rise.
For now, the vaccination teams moving through Blantyre represent both resolve and restraint proof that African health authorities can act quickly, and evidence of how constrained their choices remain. Whether this latest campaign becomes another temporary reprieve or a step toward breaking the cycle will depend on what follows once the emergency passes.
Cholera is an old disease. Its persistence is not a failure of medicine, but of priorities.
